France To Speed Up Patient Access To Unapproved Drugs
France's regulatory agency, ANSM, plans to introduce a faster and more equitable system for access to unapproved medicines for individual patients by streamlining its “temporary use authorization” system.
You may also be interested in...
Securing accelerated assessment for a drug in any regulatory jurisdiction is a major boost for drug companies, but it does not necessarily translate into an earlier reimbursement decision.
Building manufacturing capacity, educating physicians, and reaching agreements with pricing and reimbursement bodies are just some of the hurdles CAR-T therapies have to jump over in Europe, following their approval by the EU Commission earlier this week.
Transparency on COVID-19 vaccine funding, pricing and procurement is vital if vaccine hesitancy and disinformation are to be countered, say EU parliamentarians.